NO308600B1 - Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene - Google Patents

Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Info

Publication number
NO308600B1
NO308600B1 NO964093A NO964093A NO308600B1 NO 308600 B1 NO308600 B1 NO 308600B1 NO 964093 A NO964093 A NO 964093A NO 964093 A NO964093 A NO 964093A NO 308600 B1 NO308600 B1 NO 308600B1
Authority
NO
Norway
Prior art keywords
alkyl
opt
alkoxy
substd
cycloalkyl
Prior art date
Application number
NO964093A
Other languages
English (en)
Norwegian (no)
Other versions
NO964093L (no
NO964093D0 (no
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19536263A external-priority patent/DE19536263A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO964093D0 publication Critical patent/NO964093D0/no
Publication of NO964093L publication Critical patent/NO964093L/no
Publication of NO308600B1 publication Critical patent/NO308600B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO964093A 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene NO308600B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19536263A DE19536263A1 (de) 1995-09-28 1995-09-28 Substituierte Chinolin-2-carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19605170 1996-02-13

Publications (3)

Publication Number Publication Date
NO964093D0 NO964093D0 (no) 1996-09-27
NO964093L NO964093L (no) 1997-04-01
NO308600B1 true NO308600B1 (no) 2000-10-02

Family

ID=26019051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964093A NO308600B1 (no) 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Country Status (20)

Country Link
US (2) US5726305A (fr)
EP (1) EP0765871B1 (fr)
JP (1) JPH09124606A (fr)
KR (1) KR970061869A (fr)
CN (2) CN1120157C (fr)
AT (1) ATE263155T1 (fr)
AU (1) AU728208B2 (fr)
CA (1) CA2186717A1 (fr)
CZ (1) CZ283396A3 (fr)
DE (1) DE59610950D1 (fr)
ES (1) ES2215184T3 (fr)
HU (1) HUP9602685A3 (fr)
IL (2) IL135495A (fr)
MX (1) MX9604378A (fr)
MY (1) MY133647A (fr)
NO (1) NO308600B1 (fr)
NZ (1) NZ299455A (fr)
PL (1) PL316321A1 (fr)
SG (1) SG45503A1 (fr)
SI (1) SI9600287A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20020198145A1 (en) * 1999-06-10 2002-12-26 Cognetix, Inc. MuO-conopeptides and their use as local anesthetics
CA2432642A1 (fr) * 2000-12-21 2002-08-08 Subhash P. Khanapure Composes aryle substitues en tant que nouveaux inhibiteurs selectifs de la cyclo-oxygenase-2, compositions et methodes d'utilisation
US20040146964A1 (en) * 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
EP2295060B1 (fr) 2001-12-06 2018-10-31 Fibrogen, Inc. Traitement de conditions ischémiques ou hypoxiques
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
PT1644336E (pt) * 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005034929A2 (fr) * 2003-10-10 2005-04-21 Fibrogen, Inc. Remodelage et vascularisation de tissus
EP1893186A2 (fr) * 2005-06-06 2008-03-05 Fibrogen, Inc. Methode amelioree de traitement de l'anemie
WO2006138511A2 (fr) 2005-06-15 2006-12-28 Fibrogen, Inc. Composes et procedes pour le traitement du cancer
WO2007025798A2 (fr) 2005-07-27 2007-03-08 F. Hoffmann-La Roche Ag Aryloxy quinolines et leur utilisation en tant que 5-ht6
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
JP5161793B2 (ja) * 2006-01-27 2013-03-13 フィブロジェン， インコーポレイテッド 低酸素症誘導因子（ｈｉｆ）を安定化するシアノイソキノリン化合物
WO2007101204A1 (fr) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Méthode de traitement du glaucome
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
ES2533765T3 (es) * 2006-03-30 2015-04-15 Lg Electronics Inc. Un método y un aparato para descodificar/codificar una señal de video
CN103497184A (zh) * 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
EP4095127A1 (fr) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Inhibiteurs de prolyl hydroxylase et procédés d'utilisation
EP2111399A2 (fr) * 2006-12-18 2009-10-28 Amgen Inc. Composés de naphtalénone présentant une activité inhibititrice de prolyle hydroxylase, compositions et utilisations de ceux-ci
US8048892B2 (en) * 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683956C (fr) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones et azaquinolones inhibant la prolyl hydroxylase
US7569726B2 (en) * 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137084A2 (fr) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones inhibant l'activité de la prolyl hydroxylase
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2009002533A1 (fr) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Thérapies d'affection abdominale inflammatoire
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
ES2575154T3 (es) * 2009-12-17 2016-06-24 Merck Sharp & Dohme Corp. Moduladores alostéricos positivos del receptor M1 de quinolina amida
DK2672823T3 (en) 2011-02-07 2016-11-28 Biogen Ma Inc S1P-modulating agents
NO2686520T3 (fr) 2011-06-06 2018-03-17
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2905898T3 (es) 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
SG11201500339XA (en) * 2012-07-27 2015-02-27 Biogen Ma Inc Atx modulating agents
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
CN113302175A (zh) 2018-11-09 2021-08-24 维瓦斯治疗公司 双环化合物
CN114072207B (zh) 2019-04-16 2024-03-29 维瓦斯治疗公司 双环化合物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
EP0541042A1 (fr) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Dérivés d'acide pyridine 2,4- et 2,5-dicarboxyliques, leur procédé de préparation et leur utilisation comme médicaments
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK122693D0 (da) * 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
EP0650960B1 (fr) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Esters de carboxamide hétérocycliques substitués, leur préparation et leur utilisation comme médicaments
DE59401924D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
HUP9602685A2 (hu) 1998-09-28
CA2186717A1 (fr) 1997-03-29
CN1282737A (zh) 2001-02-07
JPH09124606A (ja) 1997-05-13
EP0765871A1 (fr) 1997-04-02
MX9604378A (es) 1997-03-29
AU728208B2 (en) 2001-01-04
HUP9602685A3 (en) 2001-04-28
IL119302A0 (en) 1996-12-05
US5726305A (en) 1998-03-10
CN1154365A (zh) 1997-07-16
CZ283396A3 (en) 1997-04-16
EP0765871B1 (fr) 2004-03-31
KR970061869A (ko) 1997-09-12
MY133647A (en) 2007-11-30
NO964093L (no) 1997-04-01
NO964093D0 (no) 1996-09-27
DE59610950D1 (de) 2004-05-06
IL135495A (en) 2002-12-01
NZ299455A (en) 1997-06-24
CN1120157C (zh) 2003-09-03
ATE263155T1 (de) 2004-04-15
AU6583896A (en) 1997-04-10
HU9602685D0 (en) 1996-11-28
PL316321A1 (en) 1997-04-01
SG45503A1 (en) 1998-01-16
US5719164A (en) 1998-02-17
SI9600287A (en) 1997-04-30
ES2215184T3 (es) 2004-10-01

Similar Documents

Publication Publication Date Title
NO308600B1 (no) Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
FI943579A (fi) Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet
CA2266107A1 (fr) Lactames et imides heterocycliques d'aralkyle et d'aralkylidene
DK436289D0 (da) Cycloalkyl-substituerede glutaramidderivater, farmaceutiske praeparater indeholdende disse forbindelser, forbindelserne til medicinsk anvendelse og deres anvendelse til fremstilling af laegemidler til behandling af hypertension, hjertesvigt eller renal insufficiens
DE69429708D1 (de) Galanthamin Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
IE881994L (en) Substituted azepines and pyrrolidines
DK0667768T3 (da) Anvendelse af toremifen til behandling af SLE
PH24782A (en) Composition containing a penem or carbapenem antibiotic and the use of the same
IL105020A0 (en) Carbapenem derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUT34210A (en) Process for producing new cepheme-carboxylic acid derivatives and pharmaceutical compositions containing them as active ingredients
IL88921A0 (en) Anti-psychotic pharmaceutical compositions containing a certain imidazobenzodiazepine
BR1100564A (pt) Formas cristalinas de mono-hidrato do cloridrato de endo-2,3-dihidro-n-(8-metil-8-azabiciclo[3.2.1]oct-3-il)-2 - -oxo-1h-benzimidazol-1-carboxamida e de mono-hidrato do cloridrato de endo-3-etil-2,3-di-hidro-n-(8-metil-8-azabiciclo[3.2.1]oc t-3-il)-2-oxo-1h-benzimidazol-1-carboxamida como antagonistas do 5-ht
DK165923C (da) 2,3-dihydro-1-(8-methyl-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon i praktisk taget ren form, fremgangsmaader til dens fremstilling, dens anvendelse som og til fremstilling af et laegemiddel samt farmaceutisk praeparat indeholdende den
MX9805321A (es) Tieno[2,3-b]pirazolo[3,4-d]piridin-3-onas para incrementar la eritropoyesis.
IE35218L (en) Azepine derivatives
ITTE930001A0 (it) Procedimento per l'arricchimento del tenore in zeoliti di sottoprodot-ti delle cave di blocchetti di "tufo litoide"
IT1233837B (it) Derivati diidropiridinici, loro preparazione e impieghi farmaceutici.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees